Comparative Review of Oral P2Y12 Inhibitors.
P T. 2018 Jun;43(6):352-357
Authors: Koski R, Kennedy B
Current practice guidelines recommend dual antiplatelet therapy comprised of aspirin and a purinergic signaling receptor Y12 (P2Y12) for patients following acute coronary syndrome. This article compares the efficacy, safety, and other characteristics of the three available oral P2Y12 inhibitors-clopidogrel, prasugrel, and ticagrelor.
PMID: 29896034 [PubMed]